Trevi Therapeutics Inc (OQ:TRVI)

Business Focus: Biopharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 195 Church St Fl 14
NEW HAVEN CT 06510-2009
Tel: N/A
IR: See website
Key People
David P. Meeker
Chairman of the Board
Jennifer L. Good
President, Chief Executive Officer, Co-Founder, Director
Thomas R. Sciascia
Co-Founder, Chief Medical Officer
Christopher J. Seiter
Chief Financial Officer
Helena Brett-Smith
Chief Development Officer
Business Overview
Trevi Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing Nalbuphine ER for chronic pruritus. Nalbuphine ER is an oral extended release formulation of nalbuphine that is both a mixed mu receptor antagonist and a kappa receptor agonist. The Company is developing Nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson's disease.
Financial Overview
For the fiscal year ended 31 December 2018, Trevi Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders excluding extraordinary items increased from $4.5M to $25.6M. Higher net loss reflects Research and development - Balancing val increase from $6M to $13.9M (expense), Change in fair value of Series C redeema increase from $0K to $2.1M (expense).
Employees: 16 as of Mar 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $270.16M as of Dec 31, 2018
Annual revenue (TTM): $0.00M as of Dec 31, 2018
EBITDA (TTM): -$18.39M as of Dec 31, 2018
Net annual income (TTM): -$25.58M as of Dec 31, 2018
Free cash flow (TTM): -$18.45M as of Dec 31, 2018
Net Debt Last Fiscal Year: N/A
Shares outstanding: 17,771,751 as of May 7, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization